STAT5h
Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...
Acrivon Therapeutics, Inc.: Promising Advancements and Strong Buy Rating Backed by Innovative Pipeline and Solid Financial Position
TD Cowen analyst Marc Frahm has maintained their bullish stance on ACRV stock, giving a Buy rating today. Marc Frahm has given his Buy rating ...